​

Protara Therapeutics Stock (NASDAQ:TARA)

ForecastOwnershipFinancialsChart
Protara Therapeutics by TradingView

Previous Close

$5.32

52W Range

$2.77 - $7.82

50D Avg

$6.08

200D Avg

$4.67

Market Cap

$202.98M

Avg Vol (3M)

$1.07M

Beta

1.44

Div Yield

-

TARA Company Profile

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

28

IPO Date

Oct 22, 2014

Website

TARA Performance

TARA Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-64.55M$-49.15M$-43.61M
Net Income$-57.44M$-44.60M$-40.42M
EBITDA$-64.55M$-48.82M$-43.27M
Basic EPS$-1.34$-2.17$-3.57
Diluted EPS$-1.34$-2.17$-3.57

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
NTHINeonc Technologies Holdings, Inc.
GNFTGenfit S.A.
SLSSELLAS Life Sciences Group, Inc.
OABIOmniAb, Inc.
SGMOSangamo Therapeutics, Inc.
CDXSCodexis, Inc.
PRLDPrelude Therapeutics Incorporated
IVVDInvivyd, Inc.
OBIOOrchestra BioMed Holdings, Inc.
MDWDMediWound Ltd.